BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME

The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.

Saved in:
Bibliographic Details
Main Authors JUDD, Andrew S, SULLIVAN, Gerard M, WELCH, Dennie S, BENNETT, Nathan B, DOHERTY, George, CULLEN, Steve C, HAIGHT, Anthony R, KUNZER, Aaron R, TAO, Zhi-Fu, WENDT, Michael D, ACKLER, Scott L, SOUERS, Andrew J, WANG, Xilu, SHEN, Xiaoqiang, MARIN, Violeta L, SONG, Xiaohong, BOGHAERT, Erwin R, FREY, Robin R
Format Patent
LanguageEnglish
Published 28.07.2017
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
Bibliography:Application Number: SG20171104710P